Following children with muscular dystrophy in western China over time
Follows children with Duchenne and Becker muscular dystrophy to track how their disease changes.
Plain-language title generated from the registry record
Registry title: A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children
Key facts
- Where
- Chengdu, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for boys aged 1 to 18 years with genetically confirmed Duchenne or Becker muscular dystrophy. They are followed over time to see how the disease changes. No treatment is given.
- Age
- 1 to 18 years
- Sex
- Male only
- Disease stage
- Genetically confirmed Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD)
- Biomarker or test result
- Genetically confirmed diagnosis of DMD or BMD
Main reasons for not taking part
- Other nerve and muscle diseases that could confuse the results
- Taking part in another treatment trial that could affect how the disease progresses
- Severe other illnesses that prevent finishing the study assessments
- Cannot give consent or follow the study procedures
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Source: NCT07511920, who can take part
Where in China
- West China Second University Hospital, Sichuan UniversityChengdu, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- West China Second University Hospital
- Trial code
- NCT07511920
- Record updated
- 6 April 2026
- Original description
This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat distribution), clinical laboratory tests, and cardiopulmonary imaging-to delineate comprehensive disease trajectories. By analyzing how these factors change over time in a large cohort, the study seeks to develop a robust model that can identify patterns of disease progression. The ultimate goal is to generate evidence that may aid in forecasting individual patient outcomes and inform the future development of personalized rehabilitation and therapeutic strategies.Read full original descriptionShow less
A Real-World, Multicenter Cohort Study on the Natural History of Duchenne and Becker Muscular Dystrophy in Children From Western China
This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat distribution), clinical laboratory tests, and cardiopulmonary imaging-to delineate comprehensive disease trajectories. By analyzing how these factors change over time in a large cohort, the study seeks to develop a robust model that can identify patterns of disease progression. The ultimate goal is to generate evidence that may aid in forecasting individual patient outcomes and inform the future development of personalized rehabilitation and therapeutic strategies.
Inclusion: Male participants with genetically confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD); Age range: 1 to 18 years old (adjust to your actual age limit); Ability to complete study assessments and follow-up visits; Participants or legal guardians provide written informed consent.
Exclusion: Participants with other neuromuscular disorders that may confound natural history data; Participation in another interventional clinical trial that could affect disease progression; Severe comorbidities that prevent completion of study assessments; Inability to provide informed consent or comply with study procedures.